EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
N Rajea, X Leleub, A Lesokhinc, M Mohtyd, A Nookae, E Leipf, U Conteg, A Viqueirah, V Blunki, S Manierj
a Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States
b Centre Hospitalier Universitaire de Poitiers, Poitiers, France
c Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States
d Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France
e Winship Cancer Institute, Atlanta, United States
f Pfizer Inc, Cambridge, United States
g Pfizer Inc, New York, United States
j Lille University Hospital, Lille, France
Ver másLido
1185
Vezesque se leu este artigo
379
Total PDF
806
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 25 | 13 | 38 |
| 2025 5 | 60 | 11 | 71 |
| 2025 4 | 50 | 17 | 67 |
| 2025 3 | 58 | 14 | 72 |
| 2025 2 | 41 | 24 | 65 |
| 2025 1 | 43 | 19 | 62 |
| 2024 12 | 31 | 12 | 43 |
| 2024 11 | 50 | 13 | 63 |
| 2024 10 | 52 | 23 | 75 |
| 2024 9 | 61 | 21 | 82 |
| 2024 8 | 55 | 27 | 82 |
| 2024 7 | 41 | 27 | 68 |
| 2024 6 | 45 | 34 | 79 |
| 2024 5 | 46 | 28 | 74 |
| 2024 4 | 65 | 13 | 78 |
| 2024 3 | 32 | 15 | 47 |
| 2024 2 | 22 | 12 | 34 |
| 2024 1 | 9 | 12 | 21 |
| 2023 12 | 7 | 18 | 25 |
| 2023 11 | 8 | 18 | 26 |
| 2023 10 | 5 | 8 | 13 |
Mostrar tudo
